Annual reports
Our Annual Report provides a wide range of information about our global business and how we are working, both within the company and in partnership with others, to meet complex healthcare challenges and deliver life-changing medicines for people worldwide.
Latest Stock Exchange announcements
-
US FDA approves Lumoxiti (moxetumomab pasudotox-tdfk) for certain patients with relapsed or refractory hairy cell leukaemia
-
Tezepelumab granted Breakthrough Therapy Designation by US FDA
-
Board Appointments
-
Transparency Directive Voting Rights and Capital
-
Update on TULIP 1 Phase III trial for anifrolumab in systemic lupus erythematosus
Upcoming events
Payment date: first interim dividend
Year-to-date and Q3 2018 Results
Sustainability
At AstraZeneca, we want to be valued and trusted by our stakeholders as a source of great medicines over the long term.
Our new sustainability strategy, ‘Securing our Future’, drives our enhanced efforts, sets a clear path for the years ahead and identifies ambitious commitments and targets. Our sustainability commitments are driven by our Purpose and Values and underpin our business model to support the delivery of our business strategy.
As we look ahead to pursuing our science-led strategy in the years up to 2025, we have identified three priority areas. We want to ensure that we broaden access to healthcare, minimise our environmental footprint, and ensure ethics and transparency underpin everything we do.
Read moreAnnual Report
2016
2015
2006-2014
Investor enquiries
Main Contacts
-
Annual Reports
Our Annual Report provides a wide range of information about our global business.
-
Shareholder FAQs
Answers to frequently asked shareholder questions.
-
Our Pipeline
Our pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development
